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ABSTRACT:  
When bleeding from neovascularization of the disc or neovascularization of the retina may develop preretinal 
hemorrhage or vitreous hemorrhage. The risk of vitreous hemorrhage is higher with extensive disc or retinal 
neovascularization. Hemorrhages usually occur spontaneously and cause a sudden appearance of floating 
opacities. New approaches to neurophysiological diagnostics and treatment of diabetic vitreal hemorrhages were 
studied in the work. To achieve the goal, an experiment was conducted with the participation of 83 patients. For 
the study, the patient's demographic data, indication for injection, intrauterine injection type, systemic risk 
factors and ocular complications were used. It has been established that anti-VEGF injections play an important 
role in the treatment of patients. The method studied can be used to dynamically evaluate the function of the 
visual analyzer. 
 




Diabetic retinopathy (DR) is the leading cause of vision 
loss in working-age populations worldwide[1-4]. These 
causes of vision loss are often mediated by a common 
pathogenetic process – functional and structural 
disorders of ganglion cells of the retina and optic nerve[5-
6], which determines the urgency of evaluating his 
condition, including neurophysiological methods, one of 
which is the method of visual evoked response potentials 
(ERP)[7-8]. 
 
These cause of vision loss are often mediated by a 
common pathogenetic process such as functional and 
structural disorders of ganglionic cells of retina and optic 
nerve[5-6]. This state determines the sense and urgency of 
evaluating its condition, having used some 
neurophysiological methods, one of which is the well 
known and high useful method of visual evoked 
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Retinal ischemia is the leading factor in pathophysiology 
of proliferative diabetic retinopathy (PDR). Angiogenic 
mediators such as insulin-like growth factor-1, 
erythropoietin, fibroblast growth factor and vascular 
endothelial growth factor (VEGF) are released secondary 
to retinal ischemia. They lead to the formation of 
neovascular structures in the retina [9-11]. One of the 
common ways the VH arises are those neovascular 
structures hemorrhages. Contraction of the fibrous 
component can increase the tendency of neovascular 
structures to bleed, also often caused associated visual 
nerve damage and lead to loss of vision. In the most of 
cases VH is treated surgically. But the high risk of 
complications after vitrectomy, sometimes negotiates 
surgical procedure[12-14]. 
 
Panretinal photocoagulation (PRP) is the gold standard 
in PDR treatment which can reduce the risk of severe 
visual loss by 50-60%[15-16]. The patients who do not 
receive timely PRP develop serious vision loss within 5 
years[17]. But 4.5% of patients show disease progression 
that ultimately lead to pars plana vitrectomy (PPV), 
although the PRP was considered adequate[18]. 
 
 




Photocoagulation therapy not be possible in eyes with 
intravitreal opacity such as VH. This condition leads to 
the progression of neovascular tissue and may result in 
persistent VH, recurrent VH, or development of TRD. 
Currently, in patients whose hemorrhage does not clear 
spontaneously, PRP is performing after clearing the 
media[19]. 
 
Anti-VEGF drugs prevent the formation of new 
vasculature by directly affecting VEGF. VEGF is a 40 
kDa dimeric glycoprotein that is produced by hypoxic 
stimulation in different cells of the retina: vascular 
endothelium, retinal pigment epithelial cells, Müller 
cells[20]. 
 
The first VEGF-A inhibitor, bevacizumab (Avastin), was 
approved by the US Food and Drug Administration 
(FDA) in 2004 for the first-line treatment of metastatic 
colorectal cancer. It is a monoclonal antibody (149kDa) 
that binds to all isoforms of VEGF-A and is now being 
used as an off label intravitreal drug for the treatment of 
retinal vascular disorders[21]. The first VEGF-A 
inhibitors in ophthalmology, pegaptanib (Macugen) and 
ranibizumab (Lucentis), were approved in 2004 and 
2006, respectively. Ranibizumab is an Fab fragment of 
the humanized monoclonal antibody (48kDa) and has an 
affinity for all VEGF isoforms. The smaller molecule 
compared to Bevacizumab allows better retinal 
penetration[22]. Aflibercept (Eylea) is a recent anti-VEGF 
therapy approved in 2011. This agent has shown 
significant gain in visual acuity and improvement in 
morphological outcomes[23-24]. It’s estimated that 
concentration of VEGF was significantly higher in eyes 
with VH due to DR (821 ± 949 pg/ml) than in non-DR 
hemorrhage (2.75 ± 7.5 pg/ml, P < 0.01, chi-square test) 
or non-DR with no VH (less than detectable level, 
P < 0.01, chi-square test)[25]. 
 
Intravitreal anti-VEGF agents have been used in DR 
treatment for diabetic macular edema, preretinal 
hemorrhage, and neovascularization and as preoperative 
adjuvant therapy in PDR cases[26]. 
 
Anti-VEGF agents block new vessel formation and also 
induce regression of existing vessels [27]. So, they can 
theoretically prevent new hemorrhages from preexisting 
or new loci in VH patients. And can be successful in the 
treatment VH. Because of the drug’s short half-life, it is 
expected that IVB is not effective against recurrent 
hemorrhage in the long term. 
 
In a study by the Diabetic Retinopathy Clinical Research 
Network (DRCRnet), researchers applied 
intravitrealranibizumab to 125 eyes and intravitreal 
saline to 136 eyes of diabetic patients with VH that 
precluded PRP. At 16 weeks after injection, eyes 
injected with ranibizumab showed a greater 
improvement in VA, lower rate of recurrent hemorrhage 
and significantly higher rate of PRP completion 
compared to the saline-injected group[28]. However, in a 
later report of results at 1 year, they reported no 
significant differences in VA outcomes or surgery 
rates[29]. 
 
The ideal interval for repeated IVB injections in cases of 
PDR-associated VH has not been clearly established. A 
second injection in eyes not exhibiting signs of 
hemorrhage clearance 4-6 weeks after the first injection. 
Repeated IVB injections were administered to eyes that 
did not show reduced hemorrhage or developed recurrent 
hemorrhage in early follow-up[30]. In general, the visual 
acuity (VA) of PDR patients can be expected to return to 
pre-hemorrhage levels after the VH is completely 
resorbed[31]. 
 
In practice, ophthalmologists often face a situation where 
the nature or degree of VH does not allow 
ophthalmoscopically assess the condition of the fundus, 
retina, optic disc. The dynamics of restoration or 
deterioration of the function of these structures depends 
on the nature, massiveness, other parameters of VH. 
Monitoring their condition presents difficulties in 
diagnosis, with the outcome of VH largely dependent on 
the state of the structures described. One of the 
additional methods of evaluation, the dynamics of 
recovery or deterioration of the optic nerve function with 
VH is the VLP method. In the context of this problem – 
the achievement of better treatment outcomes, outcomes 
of VH, the authors evaluated the diagnostic significance 
of the early-day components of visual evoked potentials 
using flash stimulation. 
 
The purpose of this article is evaluation of the outcomes 
of intravitreal Ranibizumab or Aflibercept use in patients 
with a vitreous hemorrhage (VH) secondary to 
proliferative diabetic retinopathy (PDR) and evaluate 
reasons and diagnostical effectiveness of using method 
of visual evoked response potentials. With the present 
study, we aimed to evaluate the effects of IVB on 
hemorrhage clearance time, need for surgery and final 
VA results in diabetic patients with VH. 
 
MATERIALS AND METHODS: 
During the experiment 83 eyes were examined of 83 
patients (33 male, 50 female) with type 2 diabetes 
mellitus. Study eyes had vitreous hemorrhage from PDR 
with or without precluding partial panretinal 
photocoagulation and include at least 6 month of follow-
up. Most patients had poor glycemic control with a mean 
HbA1C of 9,2±1.32%. 
 
 




Patients were randomized into 3 groups: eyes treated 
with IV Ranibizumab (group 1, n=32) eyes treated with 
IV Aflibersept (group 2, n=29) and eyes not treated with 
IV injection (group 3, n=22). Mean age was 65.2±5.6 
years in group 1 and 64.1±4.2 in group 2 and 61.8±4.8 in 
group 3 (p=0.441). Follow-up was scheduled for 1 and 4 
weeks afterwards and then every 4–6 weeks for the next 




Initial best-corrected visual acuity (BCVA) was 
measured using the Snellen chart: VA during follow-up; 
intraocular pressure (IOP); gonioscopy; slit-lamp 
examination; VH status; ultrasonography; dilated 
examination of the contra lateral eye; visual evoked 
potentials; VH clearance time was defined as the time 
until primary vessels in the posterior pole and the optic 




Vitrectomizedeyes, patients with simultaneous bilateral 
VH, advanced glaucoma, rubeosisiridis, tractional retinal 
detachment, corneal or anterior segment pathology, 
active ocular infection, uncontrolled systemic 
hypertension, history of thromboembolism, coagulation 
disorder. 
 
Patients who were treated by intravitral injections 
injection and those who were followed without 
intravitreal therapy were compared in terms of visual 
acuity (VA) change, final VA, VH clearance time, rate 
of surgical intervention. 
 
The parameters evaluated included patient’s 
demographic data, indications for injection, type of 
intravitreal injection used, systemic risk factors and 
ocular complications. 
 
RESULTS AND DISCUSSION: 
Taking into account that the purpose of the work 
includes the evaluation of the diagnostic significance of 
Visual evoked potentials, we briefly describe the 
neurophysiology of this method. In this work, the VEP 
was not evaluated for the chess pattern of stimulation in 
connection with the conceptual statement of the problem 
of isolating the state of cells forming the structures of the 
optic nerve, primary projections of fibers Lemniscus 
lateralis – visual cortex. For such a task, it is appropriate 
to use flash stimulation for a flash of red light generated 
by a matrix of LEDs, a flash duration of up to 0.1 ms, 
and a stimulation period of 1000 ms. With flash 
stimulation, it is possible to record distinctly the so-
called super-early VEP components (designation N0 or 
P0 due to possible biphasic response, have a 
development time of up to 20 ms), are generated as a 
result of the optic nerve response – lemniscus lateralis – 
primary visual cortex. Early induced responses of the 
nervous system (P1-N1, matching latent periods of 20-
140 ms) reflect the activity of primary visual centers, the 
primary response of the cerebral cortex to afferent 
activation and the initial stages of the inclusion of 
modal-nonspecific brain structures in response. The 
components of the intermediate phase (P2-N2 – the 
development time of 140-160 ms) are the potential that 
arises from the activation and inclusion of primary 
associative brain zones in the processing of visual 
information, at this stage, the limbic-reticularly 
connected mechanisms of neuronal excitation 
development, P3 components -N3 (development time 
160-270 ms and more) are mainly considered 
conditioned by activity of the cerebral cortex in close 
interaction with limbic structures and recursion of the 
afferent flow in associative zonestory. 
 
Intravitreal injections were given in the operating room 
under the topical anesthesia. All patients gave their 
informed consent. 10% Povidone iodine was used for 
skin preparation while 5% was instilled into the 
conjunctival sac before and after injection in all patients. 
No topical antibiotics were given before and after the 
procedure. Visual acuity changes in the study groups is 
shown in Figure 1. 
 
 
Figure 1 Visual acuity changes in the study groups 
 
Table 1 Results dynamics 
The difference between initial and final VA according Snellen chart was VH clearance time was 
0.32 ± 0,1 in group 1, 
0.343 ± 0,11 in group 2 
0,19 ± 0.09 in control group (p=0.01). 
1.92 ± 0,4 months in group 1,  
2.12 ± 0.5 months in group 2 (p=0.146), 
3.13 ± 0.6 months in control group (p=0.048) 
 
  




Dosage of intravitrealranibizumab given was 0.05ml (10 
mg/ml) and aflibersept was given in the dosage 0.05ml 
(40mg/ml). Injection site varied between the 
superotemporal quadrant, inferotemporal and 
superonasal depending on the surgeon’s access. 
Injections were given 4mm from the limbus for phakic 
patients and 3.5mm for pseudophakic patients. Patients 
were reviewed one day, one week and one month post 
injection, to assess their visual acuity and check intra 
ocular pressure (Table 1). 
 
Dynamics of LP VIZ for early-stage components of VIZ 
(mean values of latent periods (LP) of early-stage 
components of VIZ): 
Initial 28, 1 ± 2, 4; final results 24.5 ± 1, 6 in group 1,  
Initial 26, 4 ± 1, 9; final results 23.9 ± 1, 6 in group 2,  
Initial 28, 9 ± 2, 5; final results 28.3 ± 1, 9 in group 3, 
12, 8 ± 2, 3 – healthy people. 
VH clearance time shown in Figure 2. 
 
 
Figure 2 VH clearance time 
 
In the study of VLPs, diagnostic features, such as 
asymmetry and decrease in the level of (μV) of 
responses, increased response time of early-day 
components and the restoration of late cortical 
components were also noted. An increase in LP was 
detected, starting with super early components (24.9 ms 
± 1.9). A significant increase in the recovery time of the 
cortical potential in the occipital cortical leads (320.6 ± 
34.9) in this contingent of patients is probably also due 
to damage to the ganglion cells. Significant differences 
of late cortical responses with an increase in LPPs mean 
their diagnostic significance not only as markers of the 
violation of cortical neurodynamics, but reflects a 
probable connection with the consequences of VH. 
Additional interpretation of the changes in the 
neurophysiological response of brain integrative systems 
as a result of the primary lesion of ganglion cells and 
optic nerve structures seems relevant for further study 
and application as a possible new marker in the 




Figure 3 Vitrectomy rates 
 
The impairment of the function of the optic nerve from 
the data of the early-day components of visual evoked 
potentials in this study was highly consistent with 
clinical, ophthalmoscopic disorders and manifested itself 
in the form of asymmetry of the latent periods of 
response of a healthy and compromised eye, showing a 
clear dynamics during the treatment. At the same time, 
the changes in the time of development of the 
components of the VIZ primarily reflect stable, mainly 
structural changes in the generator structures, the level of 
the amplitude of the VLV responses to the outbreak is 
more dynamic for all levels of generation, depending on 
changes in the functional state, pharmacological effects 
and other dynamic factors. 
 
                     
Figure4 Recurrent diabetic vitreous hemorrhageBCVA – light perception             Figure5 3 days after intravitrealRanibizumab injection 





                    
Figure6 7 days after intravitreal Ranibizumab injection                 Figure7 1 month after intravitreal Ranibizumab injection BCVA 20/ 
200 
 
                       
Figure8 1 year after intravitreal Ranibizumab injection BCVA 20/ 100           Figure9Partial diabetic vitreous hemorrhage BCVA  20/200 
 
                       
Figure10 7 days after intravitrealAflibercept injection            Figure11 1 month after intravitrealAflibercept injection BCVA 20/40 
 
Vitrectomy was recommended for eyes that did not show 
hemorrhage clearance within the first 4-6 months or 
developed recurrent VH. The 20,1% from group 1 and 
23,5% from group 2 and 45.6 % from control group 
underwent PPV due to persistent or recurrent VH 
(p=0.048) (Figure 3). 
 
IVI decreases the number of cases requiring surgery. 
Clinical examples before treatment and after two 
different patients are presented in Figures 4-11. 
 
CONCLUSION AND FUTURE PROSPECTIVE: 
This study showed important role IV anti VEGF 
injections in the management of patients with VH 
secondary to PDR. IV injections was found effective in 
the changes of BCVA in compare with no IVI. 
Determined that Intravitreal injection of anti–VEGF can 
reduce vitrectomy rates (and risks associated with 
vitrectomy). Although VH clearance time was shorter in 
group with IVI, the different was not statistically 
significant. 
 
During the study, the diagnostic signs of the VEP were 
determined. This is an asymmetry and a decrease in the 
level of responses, an increase in the response time of 
early-day components, and the restoration of late cortical 
components. It has been established that the change in 
the development time of the components of the VIZ 




mainly reflects stable, structural changes in the generator 
structures, the level of the amplitude of the VLV 
responses to the outbreak is more dynamic for all levels 
of generation, depending on changes in the functional 
state, pharmacological effects and other dynamic factors. 
 
The VLP research method is informative at VH and can 
be included in the diagnostic plan if the eye structures 
are difficult to visualize and for the dynamic evaluation 
of the visual analyzer function. 
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